Page 60 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine LuPSMA response patterns on PSMA PET

doi: 10.1016/j.euo.2020.07.002 17. Pathmanandavel S, Crumbaker M, Nguyen A, et al. The
prognostic value of posttreatment 68Ga-PSMA-11 PET/
7. Young H, Baum R, Cremerius U, et al. Measurement
of clinical and subclinical tumour response using CT and 18F-FDG PET/CT in metastatic castration-resistant
177
[ F]-fluorodeoxyglucose and positron emission tomography: prostate cancer treated with Lu-PSMA-617 and NOX66 in
18
review and 1999 EORTC recommendations. European a phase I/II trial (LuPIN). J Nucl Med. 2022;64:69-74.
organization for research and treatment of cancer (EORTC) doi: 10.2967/jnumed.122.264104
PET study group. Eur J Cancer. 1999;35(13):1773-1782.
18. Andrei G, Wolfgang W, Robert T, Matthias E. Predictive value
doi: 10.1016/S0959-8049(99)00229-4 of interim PSMA PET during 177Lu-PSMA radioligand
therapy for overall survival in patients with advanced
8. Jansen BHE, Cysouw MCF, Vis AN, et al. Repeatability
of quantitative 18 F-DCFPyL PET/CT measurements in prostate cancer. J Nuclear Med. 2019;60(supplement 1):73.
metastatic prostate cancer. J Nucl Med. 2020;61(9):1320-1325. 19. Heinzel A, Boghos D, Mottaghy FM, et al. Ga-PSMA
68
PET/CT for monitoring response to 177 Lu-PSMA-617
doi: 10.2967/jnumed.119.236075
radioligand therapy in patients with metastatic castration-
9. Scher HI, Morris MJ, Stadler WM, et al. Trial design and resistant prostate cancer. Eur J Nucl Med Mol Imaging.
objectives for castration-resistant prostate cancer: Updated 2019;46(5):1054-1062.
recommendations from the prostate cancer clinical trials doi: 10.1007/s00259-019-4258-6
working group 3. J Clin Oncol. 2016;34(12):1402-1418.
20. Gafita A, Calais J, Grogan TR, et al. Nomograms to
doi: 10.1200/JCO.2015.64.2702
predict outcomes after 177Lu-PSMA therapy in men
10. Pathmanandavel S, Crumbaker M, Yam AO, et al. with metastatic castration-resistant prostate cancer: An
177Lu-PSMA-617 and idronoxil in men with end-stage international, multicentre, retrospective study. Lancet Oncol.
metastatic castration-resistant prostate cancer (LuPIN): 2021;22:1115-1125.
Patient outcomes and predictors of treatment response in a doi: 10.1016/s1470-2045(21)00274-6
phase I/II trial. J Nucl Med. 2022;63(4):560-566.
21. Kuo PH, Morris MJ, Hesterman J, et al. Quantitative
doi: 10.2967/jnumed.121.262552
68 Ga-PSMA-11 PET and clinical outcomes in
11. Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements metastatic castration-resistant prostate cancer
on PSMA PET/CT response assessment criteria in prostate following 177 Lu-PSMA-617 (VISION trial). Radiology.
cancer. Eur J Nucl Med Mol Imaging. 2020;48:469-476. 2024;312(2):e233460.
doi: 10.1007/s00259-020-04934-4 doi: 10.1148/radiol.233460
12. Pollard JH, Raman C, Zakharia Y, et al. Quantitative test- 22. Current K, Meyer C, Magyar CE, et al. Investigating PSMA-
68
retest measurement of Ga-PSMA-HBED-CC in tumor and targeted radioligand therapy efficacy as a function of cellular
normal tissue. J Nucl Med. 2020;61(8):1145-1152. PSMA levels and intratumoral PSMA heterogeneity. Clin
Cancer Res. 2020;26(12):2946-2955.
doi: 10.2967/jnumed.119.236083
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response doi: 10.1158/1078-0432.CCR-19-1485
evaluation criteria in solid tumours: Revised RECIST 23. Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific
guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. membrane antigen heterogeneity and DNA repair defects in
prostate cancer. Eur Urol. 2019;76(4):469-478.
doi: 10.1016/j.ejca.2008.10.026
doi: 10.1016/j.eururo.2019.06.030
14. De Wreede LC, Fiocco M, Putter H. Mstate: An R package
for the analysis of competing risks and multi-state models. 24. Beltran H, Hruszkewycz A, Scher HI, et al. The role of
J Stat Softw. 2011;38(7):1-30. lineage plasticity in prostate cancer therapy resistance. Clin
Cancer Res. 2019;25(23):6916-6924.
doi: 10.18637/jss.v038.i07
doi: 10.1158/1078-0432.CCR-19-1423
15. Stoffel MA, Nakagawa S, Schielzeth H, Goslee S. Rptr:
Repeatability estimation and variance decomposition by 25. Matuszczak M, Salagierski M. Oligometastatic disease in
generalized linear mixed‐effects models. Methods Ecol prostate cancer. Evolving paradigm: Current knowledge,
Evol. 2017;8(11):1639-1644. diagnostic techniques and treatment strategies. Arch Med
Sci. 2022.
doi: 10.1111/2041-210x.12797
doi: 10.5114/aoms/156170
16. Team RC. R: A Language and Environment for Statistical
Computing. R Foundation for Statistical Computing. Avaialble 26. Pepe P, Pepe L, Curduman M, Pennisi M, Fraggetta F. Ductal
from: https://www.r-project.org [Last accessed on 2023 Oct prostate cancer staging: Role of PSMA PET/CT. Arch Ital
17]. Urol Androl. 2024;96(1):12132.

Volume 3 Issue 3 (2025) 52 doi: 10.36922/ARNM025110011